Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03686709 · ClinicalTrials.gov registry record · NA
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
A NA study of Hepatocellular Carcinoma and Radiation Exposure, sponsored by University of Tennessee.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03686709 is a NA study of Hepatocellular Carcinoma and Radiation Exposure that is actively recruiting participants, run by University of Tennessee. The registered enrollment target is 20 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03686709, a NA study of Hepatocellular Carcinoma and Radiation Exposure, is actively recruiting participants, sponsored by University of Tennessee.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Post therapy PET/CT Imaging
Study Locations (1)
Tennessee
- University of Tennessee Medical Center - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03686709
The ClinicalTrials.gov registry entry for NCT03686709 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Post therapy PET/CT Imaging is the first listed.
NCT03686709 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT03686709 about?
NCT03686709 is a clinical study titled "Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment". The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.
What is the current status of trial NCT03686709?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2018-06-19. Estimated completion is 2019-12-31.
What conditions does trial NCT03686709 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Radiation Exposure.
What interventions are being tested in trial NCT03686709?
The interventions under investigation include: Post therapy PET/CT Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03686709?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03686709 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
RECRUITING · NA
-
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
RECRUITING · NA
-
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.